Citius Pharmaceuticals Inc
NASDAQ:CTXR
Citius Pharmaceuticals Inc
NASDAQ:CTXR
Price:
0.8124
USD
-1.6%
Market Closed
Market Cap:
$18.2m
Relative Value
The Relative Value of one
CTXR
stock under the Base Case scenario is
5.5418
USD.
Compared to the current market price of 0.8124 USD,
Citius Pharmaceuticals Inc
is
Undervalued by 85%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CTXR
Relative Value
Base Case
5.5418
USD
Undervaluation 85%
Multiples Across Competitors
CTXR Competitors Multiples
Citius Pharmaceuticals Inc Competitors
Citius Pharmaceuticals Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Citius Pharmaceuticals Inc
NASDAQ:CTXR
|
18.2m USD | 4.6 | -0.5 | -0.3 | -0.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
866.9B USD | 13.3 | 42 | 28.4 | 30.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
572.1B USD | 6.1 | 21.3 | 14.8 | 18.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
243.3B CHF | 4 | 18.9 | 11.2 | 12.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
218B GBP | 5 | 28.7 | 15.9 | 22.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
225.3B CHF | 5.2 | 20.8 | 12.9 | 16.6 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
282.6B USD | 4.3 | 15.5 | 9.6 | 11.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
240.1B USD | 103.6 | -82.1 | 380.1 | 953.2 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.4 | 10.2 | 7.6 | 8.9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.9B USD | 2.5 | 20.1 | 7.7 | 10.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117B USD | 2.4 | 16.6 | 7 | 8.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
